Search

Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system (CNS) that leads to disability in middle‐aged individuals. High rates of apoptosis and inappropriate homing are limitations for the application of stem cells in cell therapy. Preconditioning of bone marrow mesenchymal stem cells (BMSCs) with stromal cell‐derived factor 1α (SDF‐1α), also called C‐X‐C motif chemokine 12 (CXCL12), is an approach for improving the functional features of the cells. The aim of this study was to investigate the therapeutic efficacy of intranasal delivery of SDF‐1α preconditioned BMSCs in the cuprizone‐induced chronically demyelinated mice model. BMSCs were isolated, cultured, and preconditioned with SDF‐1α. Then, intranasal delivery of the preconditioned cells was performed in the C57BL/6 mice receiving cuprizone for 12 weeks. Animals were killed at 30 days after cell delivery. SDF‐1α preconditioning increased C‐X‐C chemokine receptor type 4 (CXCR4) expression on the surface of BMSCs, improved survival of the cells, and decreased their apoptosis in vitro. SDF‐1α preconditioning also improved CXCL12 level within the brain, and enhanced spatial learning and memory (assessed by Morris water maze [MWM]), and myelination (assessed by Luxol fast blue [LFB] and transmission electron microscopy [TEM]). In addition, preconditioning of BMSCs with SDF‐1α reduced the protein expressions of glial fibrillary acidic protein and ionized calcium‐binding adapter molecule (Iba‐1) and increased the expressions of oligodendrocyte lineage transcription factor‐2 (Olig‐2) and adenomatous polyposis coli (APC), evaluated by immunofluorescence. The results showed the efficacy of intranasal delivery of SDF‐1α‐preconditioned BMSCs for improving remyelination in the cuprizone model of MS. [ABSTRACT FROM AUTHOR]

Objective: Previous studies have shown that transplantation of bone marrow stromal cells (BMSCs) into the contused spinal cord improves functional recovery and that administration of Schwann cells (SCs) after spinal cord injury (SCI) facilitates axonal regeneration. Although the efficacy of these treatments have been proven, when used individually, their resulting number of regenerated axons is small and locomotor recovery is modest; therefore, we decided to research whether co-transplantation of these cells can improve the outcome. Materials and Methods: Adult male Wistar rats (n=56), each weighting 250-300 grams were used. BMSCs and SCs were cultured and prelabeled with BrdU and 1,1' dioctadecyl 3,3,3',3' tetramethylindocarbocyanin perchlorate respectively. Contusion model of SCI was performed at the T8-9 level using NYU device (New York University device). The rats were divided into seven groups, each consisting of 8 animals. These groups included: a control group, three experimental groups and three sham groups. In the control group, only a laminectomy was performed. The three experiment groups were the BMSC, SC and co-transplant groups, and 7 days after injury, they received intraspinal BMSCs, SCs and the combination of BMSCs & SCs respectively. The sham groups received serum in the same manner. Locomotion in the groups was assessed using the basso, beatie and bresnahan (BBB) test at 1, 7, 14, 21, 28, 35, 42, 49 and 56 days after SCI. Results: More significant improvement was observed in the BBB scores of the co-transplant group (p<0.05) in comparison with BMSC and SC groups. Conclusion: This study shows that co-transplantation of BMSCs and SCs may provide a powerful therapy for SCI and become required for the development of combinatory treatment strategies in the future. [ABSTRACT FROM AUTHOR]